Qiagen NV (QGEN) Earns Buy Rating from Barclays PLC

Barclays PLC restated their buy rating on shares of Qiagen NV (NASDAQ:QGEN) in a research note issued to investors on Friday, May 5th. The brokerage currently has a $33.00 target price on the stock.

A number of other analysts have also weighed in on the stock. Zacks Investment Research lowered shares of Qiagen NV from a hold rating to a sell rating in a research note on Wednesday, April 5th. TheStreet lowered shares of Qiagen NV from a b- rating to a c rating in a research note on Monday, April 24th. Deutsche Bank AG restated a buy rating on shares of Qiagen NV in a research note on Monday, January 30th. Commerzbank Ag restated a buy rating on shares of Qiagen NV in a research note on Thursday, January 19th. Finally, DZ Bank AG reaffirmed a neutral rating on shares of Qiagen NV in a report on Monday, February 6th. Seven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. The company presently has an average rating of Hold and an average price target of $28.36.

Qiagen NV (NASDAQ:QGEN) traded up 1.37% during trading on Friday, hitting $32.56. 661,246 shares of the stock were exchanged. Qiagen NV has a 52 week low of $20.73 and a 52 week high of $32.80. The firm’s 50-day moving average is $30.02 and its 200 day moving average is $29.17. The firm has a market cap of $7.41 billion, a PE ratio of 90.44 and a beta of 1.05.

WARNING: This story was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this story on another domain, it was stolen and reposted in violation of United States & international copyright law. The original version of this story can be accessed at https://www.chaffeybreeze.com/2017/05/20/barclays-plc-reaffirms-buy-rating-for-qiagen-nv-qgen-updated.html.

Several large investors have recently added to or reduced their stakes in the stock. FNY Managed Accounts LLC bought a new stake in Qiagen NV during the first quarter valued at about $103,000. Oppenheimer Asset Management Inc. bought a new stake in Qiagen NV during the first quarter valued at about $114,000. Quadrant Capital Group LLC boosted its stake in Qiagen NV by 403.4% in the first quarter. Quadrant Capital Group LLC now owns 5,517 shares of the company’s stock valued at $154,000 after buying an additional 4,421 shares during the last quarter. Riverhead Capital Management LLC boosted its stake in Qiagen NV by 402.2% in the third quarter. Riverhead Capital Management LLC now owns 5,800 shares of the company’s stock valued at $159,000 after buying an additional 4,645 shares during the last quarter. Finally, Elkfork Partners LLC acquired a new stake in shares of Qiagen NV during the fourth quarter valued at $180,000. Hedge funds and other institutional investors own 60.68% of the company’s stock.

Qiagen NV Company Profile

QIAGEN N.V. (QIAGEN) is a holding company. The Company is engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Its Sample to Insight solutions integrate sample and assay technologies, bioinformatics and automation systems. Its sample technologies are used for isolating and preparing deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and proteins from blood or other liquids, tissue, plants or other materials.

12 Month Chart for NASDAQ:QGEN

Receive News & Ratings for Qiagen NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen NV and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply